Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

2022 Alzheimer's disease facts and figures

Alzheimer s & Dementia (2022) Vol. 18, Iss. 4, pp. 700-789
Closed Access | Times Cited: 1940

Showing 1-25 of 1940 citing articles:

2024 Alzheimer's disease facts and figures

Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3708-3821
Open Access | Times Cited: 544
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Chao Gao, Jingwen Jiang, Yuyan Tan, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 391
Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
Xue Li, Xiaojin Feng, Xiaodong Sun, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 335
Western diet as a trigger of Alzheimer’s disease: From metabolic syndrome and systemic inflammation to neuroinflammation and neurodegeneration
Angelika Więckowska‐Gacek, Anna Mietelska‐Porowska, Małgorzata Wydrych, et al.
Ageing Research Reviews (2021) Vol. 70, pp. 101397-101397
Open Access | Times Cited: 235
Autophagy in Alzheimer’s disease pathogenesis: Therapeutic potential and future perspectives
Zhigang Zhang, Xifei Yang, You‐Qiang Song, et al.
Ageing Research Reviews (2021) Vol. 72, pp. 101464-101464
Open Access | Times Cited: 218
Forsythoside A Mitigates Alzheimer's-like Pathology by Inhibiting Ferroptosis-mediated Neuroinflammation via Nrf2/GPX4 Axis Activation
Chunyue Wang, Shanshan Chen, Hangyu Guo, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 5, pp. 2075-2090
Open Access | Times Cited: 182
Alzheimer’s Disease: An Updated Overview of Its Genetics
Jesús Andrade-Guerrero, Alberto Santiago-Balmaseda, Paola Jeronimo-Aguilar, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3754-3754
Open Access | Times Cited: 170
Lipopolysaccharide-Induced Model of Neuroinflammation: Mechanisms of Action, Research Application and Future Directions for Its Use
Anna Skrzypczak-Wiercioch, Kinga Sałat
Molecules (2022) Vol. 27, Iss. 17, pp. 5481-5481
Open Access | Times Cited: 136
How neurons die in Alzheimer's disease: Implications for neuroinflammation
Aman Mangalmurti, John R. Lukens
Current Opinion in Neurobiology (2022) Vol. 75, pp. 102575-102575
Open Access | Times Cited: 117
Tau-targeting therapies for Alzheimer disease: current status and future directions
Erin E. Congdon, Changyi Ji, Amber M. Tetlow, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 12, pp. 715-736
Closed Access | Times Cited: 113
The structural and social determinants of Alzheimer's disease related dementias
Paris B. Adkins‐Jackson, Kristen M. George, Lilah M. Besser, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 7, pp. 3171-3185
Open Access | Times Cited: 101
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 93
Genetic correlations between Alzheimer’s disease and gut microbiome genera
Davis Cammann, Yimei Lu, Melika J. Cummings, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 86
Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer’s disease
Yun Li, Xiaohuan Xia, Yi Wang, et al.
Journal of Neuroinflammation (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 81
Retinal pathological features and proteome signatures of Alzheimer’s disease
Yosef Koronyo, Altan Rentsendorj, Nazanin Mirzaei, et al.
Acta Neuropathologica (2023) Vol. 145, Iss. 4, pp. 409-438
Open Access | Times Cited: 81
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging
Rioghna R. Pittock, Jeremiah A. Aakre, Anna Castillo, et al.
Neurology (2023) Vol. 101, Iss. 19
Open Access | Times Cited: 81
VGG-TSwinformer: Transformer-based deep learning model for early Alzheimer’s disease prediction
Zhentao Hu, Zheng Wang, Yong Jin, et al.
Computer Methods and Programs in Biomedicine (2022) Vol. 229, pp. 107291-107291
Closed Access | Times Cited: 80
Incident dementia and long-term exposure to constituents of fine particle air pollution: A national cohort study in the United States
Liuhua Shi, Qiao Zhu, Yifan Wang, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 120, Iss. 1
Open Access | Times Cited: 80
Diet in the Prevention of Alzheimer’s Disease: Current Knowledge and Future Research Requirements
Oliwia Stefaniak, Małgorzata Dobrzyńska, Sławomira Drzymała-Czyż, et al.
Nutrients (2022) Vol. 14, Iss. 21, pp. 4564-4564
Open Access | Times Cited: 75
A global view of the genetic basis of Alzheimer disease
Christiane Reitz, Margaret A. Pericak‐Vance, Tatiana Foroud, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 5, pp. 261-277
Closed Access | Times Cited: 75
Metabolic Syndrome as a Risk Factor for Alzheimer’s Disease: A Focus on Insulin Resistance
Amaia Ezkurdia, Marı́a J. Ramı́rez, Maite Solas
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4354-4354
Open Access | Times Cited: 71
Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks
Yong Peng, Hong Jin, Ya-hui Xue, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 63
Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography
Gillian Coughlan, Tobey J. Betthauser, Rory Boyle, et al.
JAMA Neurology (2023) Vol. 80, Iss. 5, pp. 462-462
Open Access | Times Cited: 62
Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer’s disease
Wei‐Ming Su, Xiaojing Gu, Meng Dou, et al.
Journal of Neurology Neurosurgery & Psychiatry (2023) Vol. 94, Iss. 11, pp. 954-961
Open Access | Times Cited: 62
Is Alzheimer disease a disease?
Amos D. Korczyn, Lea T. Grinberg
Nature Reviews Neurology (2024) Vol. 20, Iss. 4, pp. 245-251
Closed Access | Times Cited: 60
Page 1 - Next Page

Scroll to top